Literature DB >> 17207050

Drug therapy for attention-deficit/hyperactivity disorder-like symptoms in autistic disorder.

Philip Hazell1.   

Abstract

Problems of inattention and hyperactivity affect one half of individuals with autistic disorder. Care must be taken to ensure that inattention and hyperactivity are not manifestations of other behavioural pathology seen in association with autistic disorder, as this will affect treatment decisions. The prescribing of psychotropic agents to individuals with autistic disorder is increasing but the evidence base is limited, with some exceptions, to uncontrolled studies. Substantial benefit in reducing inattention and hyperactivity is seen with atypical antipsychotics such as risperidone and quetiapine, although weight gain and sedation are common side effects. Moderate benefit is derived from methylphenidate, atomoxetine, some anticonvulsant medications, guanfacine and donepezil. Data show dexamphetamine, clonidine, clomipramine, mirtazapine, and fluoxetine are of unlikely benefit.

Entities:  

Mesh:

Year:  2007        PMID: 17207050     DOI: 10.1111/j.1440-1754.2007.00995.x

Source DB:  PubMed          Journal:  J Paediatr Child Health        ISSN: 1034-4810            Impact factor:   1.954


  14 in total

1.  Child attention deficit hyperactive disorder co morbidities on family stress: effect of medication.

Authors:  Desiree Silva; Stephen Houghton; Erika Hagemann; Peter Jacoby; Brad Jongeling; Carol Bower
Journal:  Community Ment Health J       Date:  2014-08-26

Review 2.  Asperger syndrome.

Authors:  Marc R Woodbury-Smith; Fred R Volkmar
Journal:  Eur Child Adolesc Psychiatry       Date:  2008-06-18       Impact factor: 4.785

3.  ADHD severity as it relates to comorbid psychiatric symptomatology in children with Autism Spectrum Disorders (ASD).

Authors:  Rosleen Mansour; Allison T Dovi; David M Lane; Katherine A Loveland; Deborah A Pearson
Journal:  Res Dev Disabil       Date:  2016-11-24

Review 4.  Attention-deficit/Hyperactivity Disorder in the context of Autism spectrum disorders.

Authors:  Michael J Murray
Journal:  Curr Psychiatry Rep       Date:  2010-10       Impact factor: 5.285

Review 5.  Treatment for co-occurring attention deficit/hyperactivity disorder and autism spectrum disorder.

Authors:  Naomi Ornstein Davis; Scott H Kollins
Journal:  Neurotherapeutics       Date:  2012-07       Impact factor: 7.620

6.  EVENT-RELATED POTENTIAL STUDY OF ATTENTION REGULATION DURING ILLUSORY FIGURE CATEGORIZATION TASK IN ADHD, AUTISM SPECTRUM DISORDER, AND TYPICAL CHILDREN.

Authors:  Estate M Sokhadze; Joshua M Baruth; Lonnie Sears; Guela E Sokhadze; Ayman S El-Baz; Emily Williams; Robert Klapheke; Manuel F Casanova
Journal:  J Neurother       Date:  2012-03-02

7.  Protracted cognitive effects produced by clonidine in Macaca nemestrina performing a delayed matching task.

Authors:  Jerry J Buccafusco; Scott J Webster; Alvin V Terry; Nancy Kille; Donna Blessing
Journal:  Psychopharmacology (Berl)       Date:  2008-09-11       Impact factor: 4.530

8.  A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders.

Authors:  Anna J Esbensen; Jan S Greenberg; Marsha Mailick Seltzer; Michael G Aman
Journal:  J Autism Dev Disord       Date:  2009-05-12

Review 9.  Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders.

Authors:  Brian Reichow; Fred R Volkmar; Michael H Bloch
Journal:  J Autism Dev Disord       Date:  2013-10

10.  Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity.

Authors:  Laudan B Jahromi; Connie L Kasari; James T McCracken; Lisa S-Y Lee; Michael G Aman; Christopher J McDougle; Lawrence Scahill; Elaine Tierney; L Eugene Arnold; Benedetto Vitiello; Louise Ritz; Andrea Witwer; Erin Kustan; Jaswinder Ghuman; David J Posey
Journal:  J Autism Dev Disord       Date:  2008-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.